ECOG-ACRIN Fall 2013 Meeting
GU Core Committee
Meeting Agenda
Friday November 15, 2013; 8:00 AM - 11:00 AM
Hollywood, FL

8:00-8:10: Committee Updates
Carducci
Early Modality

8:10-8:45: Bladder Cancer
Hahn
Upper Tract Concept
Hoffman-Censits/Vitaly
Superficial Bladder Concepts
Coxen Study

8:45-9:00: IROC Update
Rosen/Kinahan

9:00-10:00: Prostate Cancer
Antonarakis
E2809 Closure
Ferrari
Other Group Studies (S1216, A031201)
Antonarakis
E2813
Derleth/Ferrari/Chen

- High Risk Enough (Early Modality)
- Rationale for Combination/Sensitivity in CSPC
- Rationale for LHRH as Comparator –Acceptable?
- Meaningful hypothesized difference in outcome
- Radiation standardization/ Multimodality approach
- QOL/ Fatigue assessment
- Cost Analysis
- Alternatives

New Concepts
- Any Gaps? Radium/ Continuing AR agents
- Biomarkers of Resistance
10:00-11:00: Renal Cancer

Updates- NEXT, E2805 Correlatives/ PreCog  Haas
E1812/E1813 – Updates/Planning  Haas/Harshman
Gemcitabine/Axitinib Concept  Haas
CTEP Met inhibitor proposal (papillary RCC)  Haas/Wright
Early Resistance to Temsirolimus Biomarker Study Concept  Harris
Cabozantinib vs. Sutent Trial  Choueiri